-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

903.P1.30 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, ALL, AML, Biological, Leukemia, survivorship, bone marrow, CLL, CML, Diseases, Lymphoma (any), Non-Biological, CMML, Hodgkin Lymphoma, Therapies, chemotherapy, MDS, Non-Hodgkin Lymphoma, Pediatric, Technology and Procedures, Young Adult, cytogenetics, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, palliative care, Quality Improvement , transfusion, transplantation, NGS
Saturday, December 5, 2020: 7:00 AM-3:30 PM

Esther Natalie Oliva, MD1, Uwe Platzbecker, MD2, Guillermo Garcia-Manero, MD3, Ghulam J. Mufti, Professor4*, Valeria Santini5*, Mikkael A. Sekeres6, Rami S. Komrokji, MD7, Jeevan K. Shetty8*, Derek Tang8*, Shien Guo9*, Weiqin Liao9*, George Zhang8*, Xianwei Ha8*, Rodrigo Ito8*, Jennifer Lord-Bessen8*, Jay T. Backstrom10* and Pierre Fenaux, MD, PhD11

1Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
2Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
3The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Haemato-Oncology, King's College London, London, United Kingdom
5MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy
6Cleveland Clinic Foundation, Cleveland, OH
7Moffitt Cancer Center, Tampa, FL
8Bristol Myers Squibb, Princeton, NJ
9Evidera, Waltham, MA
10Acceleron Pharma, Cambridge, MA
11Service d’Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, France

Eri Kawata, MD, PhD1,2,3, Benjamin Hedley, PhD4*, Benjamin Chin-Yee, MD5,6, Anargyros Xenocostas, MD, FRCPC5,6, Alejandro Lazo-Langner, MD, MSc5,6, Cyrus C. Hsia, MD, BSc, FRCPC5,6,7, Kang Howson-Jan, MD, FRCPC5,6, Ping Yang, PhD, DABMGG7,8*, Michael Levy, PhD9*, Stephanie Santos9*, Chris Howlett7,9*, Hanxin Lin, PhD7,9*, Bekim Sadikovic, PhD, DABMGG, FACMG7,9* and Ian Chin-Yee, MD, FRCPC5,6,7

1Division of Hematology, Department of Medicine, London Health Sciences Centre, Kyoto-Shi, KYO, Japan
2Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
3Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan
4Department of Pathology & Laboratory Medicine, London Health Sciences Centre, London, ON, Canada
5Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada
6Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
7Department of Pathology & Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
8Cytogenetics Laboratory, London Health Sciences Centre, London, ON, Canada
9Molecular Genetics Laboratory, London Health Sciences Centre, London, ON, Canada

Prajwal Dhakal, MBBS1, Elizabeth R. Lyden, MS2*, Venkat Rajasurya, MD3*, Krishna Gundabolu, MBBS4, Chakra P Chaulagain, MD5 and Vijaya R. Bhatt, MD1

1Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE
2Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE
3Multicare Health System, Puyallup, WA
4Division of Oncology and Hematology, University of Nebraska Medical Center- Fred & Pamela Buffett Cancer Center, Omaha, NE
5Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL

Mazie Tsang, MD1, Kelly L. Schoenbeck, MD2, Kim Berry, MBA3*, Eve Cohen, RN4*, Kara Bischoff, MD4*, Nancy Shepard Lopez, NP4*, Gabriel N. Mannis, MD5 and Michael Rabow, MD, FAAHPM4*

1Hematology/Oncology, UCSF, San Francisco, CA
2Division of Hematology and Oncology, UCSF, San Francisco, CA
3Executive Finance Consultant, University of California San Francisco, San Francisco, CA
4Division of Palliative Medicine, University of California San Francisco, San Francisco, CA
5Stanford University, Stanford, CA

Samantha A Hershenfeld, MD1,2, Steven M Chan, MD, PhD1,2, Vikas Gupta, MD, FRCP, FRCPath2,3, Dawn Maze, MD, FRCPC, MSc1,2, Caroline J McNamara, MBBS1,2, Mark D. Minden1,2, Tracy Murphy, MD, FRCP, FRCPath1,2, Andre C. Schuh1,2, Hassan Sibai, MBBS1,2*, Karen W.L. Yee, MD1,2 and Aaron D Schimmer, MD, PhD1,2

1Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
2Department of Medicine, University of Toronto, Toronto, ON, Canada
3Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Tracy I. George, MD1, Mehrdad Abedi, MD2, Christopher R. Cogle3, Harry P. Erba4, Guillermo Garcia-Manero, MD5, David L. Grinblatt, MD6, Pavel Kiselev7*, Rami S. Komrokji, MD8, Chrystal U. Louis7*, Jaroslaw P. Maciejewski, MD, PhD9, Melissa Nifenecker7*, Daniel A. Pollyea, MD10, Gail J. Roboz, MD11, Michael R. Savona, MD12, Bart L. Scott, MD13, Mikkael A. Sekeres9, David P. Steensma, MD14, Michael A. Thompson, MD, PhD15 and Jay L. Patel, MD1*

1University of Utah and ARUP Laboratories, Salt Lake City, UT
2University of California, Davis, Comprehensive Cancer Center, Sacramento, CA
3University of Florida, Gainesville, FL
4Duke University, Durham, NC
5MD Anderson Cancer Center, Houston, TX
6NorthShore University HealthSystem, Evanston, IL
7Bristol Myers Squibb, Princeton, NJ
8Moffitt Cancer Center, Tampa, FL
9Cleveland Clinic, Cleveland, OH
10University of Colorado, Aurora, CO
11Weill Medical College of Cornell University New York-Presbyterian Hospital, New York, NY
12Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
13Fred Hutchinson Cancer Research Center, Seattle, WA
14Dana-Farber Cancer Institute, Boston, MA
15Advocate Aurora Health, Milwaukee, WI

Namita Joshi, PhD, MS, BPharm1*, Hrishikesh P Kale, PhD, MS, BPharm1*, Shelby Corman, PharmD, MS, BCPS1*, Kala Hill2*, Tim Wert2* and Amer M. Zeidan, MBBS, MHS3

1Pharmerit International, Bethesda, MD
2Taiho Oncology, Princeton, NJ
3Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT

Elizabeth Hubscher1*, Slaven Sikirica2*, Timothy J. Bell2*, Andrew Brown, PhD2*, Verna L Welch, PhD, MPH2*, Alexander Russell-Smith, MSc2* and Paul G D'Amico, PhD, RN, NP2

1Purple Squirrel Economics, New York, NY
2Pfizer Inc., New York, NY

Xia Wu, MD1*, Yi-Nan Jiang2*, Yue-Lun Zhang2*, Jia Chen3*, Yue-ying Mao4*, Lu Zhang, MD3*, Dao-Bin Zhou3*, Xinxin Cao, MD5* and Jian Li, MD3

1Department of Hematology, Peking Union Medical College Hospital, Beijing, China
2Peking Union Medical College Hospital, Beijing, CHN
3Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4Peking Union Medical College Hospital, Beijing, China
5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

William B Pearse, MD1, Jessica K Altman, MD2 and Sheetal M Kircher, MD1*

1Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
2Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

*signifies non-member of ASH